sever
acut
respiratori
syndrom
coronaviru
alreadi
respons
far
death
previou
pathogen
coronavirus
cov
identif
clinic
approv
drug
repurpos
combat
cov
diseas
would
allow
rapid
implement
potenti
lifesav
procedur
major
proteas
mpro
consid
promis
target
base
previou
result
relat
cov
lopinavir
lpv
hiv
proteas
inhibitor
howev
limit
evid
exist
clinic
approv
antiretrovir
proteas
inhibitor
atazanavir
atv
atv
high
interest
bioavail
within
respiratori
tract
result
show
atv
could
dock
activ
site
mpro
greater
strength
lpv
atv
block
mpro
activ
confirm
atv
inhibit
replic
alon
combin
ritonavir
rtv
vero
cell
human
pulmonari
epitheli
cell
line
primari
monocyt
impair
virusinduc
enhanc
coronavirus
cov
singlestrand
posit
sens
rna
virus
larg
envelop
nucleocapsid
abl
infect
rang
host
includ
anim
human
although
number
human
cov
known
circul
season
two
highli
pathogen
variant
emerg
st
centuri
caus
lifethreaten
infect
sever
acut
respiratori
syndrom
sarscov
middleeast
respiratori
syndrom
merscov
end
novel
variant
sarscov
appear
citizen
citi
wuhan
china
believ
spill
human
anim
reservoir
like
bat
andor
pangolin
novel
cov
phylogenet
closer
sarscov
outbreak
merscov
outbreak
sarsand
merscov
rais
intern
public
health
concern
rate
mortal
respect
soon
discoveri
contemporari
becam
pandem
threat
number
confirm
infect
ramp
global
date
respons
time
death
total
sum
sarsand
merscov
causal
daili
continu
scale
current
effect
respons
pandem
selfquarantin
social
distanc
avoid
contact
infect
uninfect
individu
flatten
viru
dissemin
curv
aim
reduc
burden
medic
resourc
prevent
loss
servic
highest
need
social
action
disrupt
viru
transmiss
rate
expect
reduc
absolut
number
infect
individu
furthermor
strategi
also
provok
sever
reduct
global
econom
activ
effect
combat
impact
infect
individu
societi
whole
essenti
identifi
antivir
drug
immedi
use
well
develop
new
drug
vaccin
longterm
solut
diseas
associ
covid
repurpos
clinic
approv
drug
fastest
pathway
toward
effect
respons
pandem
outbreak
mega
trial
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
put
forward
lopinavir
lpv
ritonavir
rtv
combin
chloroquin
cq
remdesivir
treat
lpv
rtv
remdesivir
target
viral
enzym
action
cq
target
host
cell
success
antivir
drug
often
directli
target
viral
enzym
mpro
better
lpv
rtv
includ
atv
importantli
atv
describ
reach
lung
intraven
administr
moreov
propos
secondari
use
atv
treat
pulmonari
fibrosi
suggest
drug
could
function
reach
lung
serious
need
immedi
intervent
along
seri
observ
lpv
rtv
atv
motiv
us
evalu
suscept
atv
sinc
atv
avail
clinic
treatment
alon
combin
rtv
therapi
studi
first
time
describ
mpro
target
atv
atv
alon
withrtv
could
inhibit
viral
replic
cell
cultur
model
infect
also
prevent
releas
cytokin
stormassoci
mediat
time
data
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
highlight
addit
therapeut
approach
consid
clinic
trial
target
enzym
mpro
atv
lpv
evalu
molecular
model
use
repres
structur
shown
figur
atv
occupi
region
wherea
lpv
occupi
region
calcul
free
energi
score
lpv
atv
kcalmol
respect
spontan
bind
atv
suggest
lower
energi
score
may
relat
project
abil
form
hydrogen
bond
amino
acid
residu
mpro
wherea
bind
lpv
depend
hydrophob
interact
figur
molecular
dynam
analysi
reveal
rootmeansquar
deviat
rmsd
mpro
backbon
present
differ
conform
complex
atv
lpv
figur
lpv
initi
distanc
catalyt
residu
figur
conform
chang
extend
distanc
equival
figur
project
like
limit
extent
antivir
inhibit
anoth
critic
residu
satisfactorili
distanc
bound
lpv
figur
atv
interact
figur
posit
remain
stabl
within
activ
site
independ
conform
chang
display
enzym
figur
steric
occup
cleft
enzymat
activ
site
atv
block
residu
catalyt
amino
acid
explain
stronger
interact
mpro
compar
lpv
multipl
hydrogen
bond
stationari
dock
molecular
dynam
tabl
next
evalu
whether
atv
could
inhibit
sarscov
extend
investig
inhibit
replic
atv
use
rang
differ
cellular
system
vero
cell
wellknown
model
system
produc
high
viru
titer
display
visual
cytopath
effect
viral
infect
atv
alon
combin
rtv
inhibit
infecti
viru
product
sarscov
rna
level
vero
cell
figur
b
respect
cq
use
posit
control
inclus
solidar
trial
due
encourag
preclin
clinic
result
replic
respect
atvrtv
potent
therapi
test
ec
atv
alon
cq
potenc
respect
suscept
cq
consist
recent
report
literatur
valid
analysi
atvrtv
atv
cq
cytotox
valu
cc
respect
result
indic
select
index
si
repres
ratio
cc
ec
valu
atvrtv
atv
cq
respect
show
atvrtv
high
therapeut
potenti
greater
cq
sinc
result
regard
pharmacolog
activ
atv
atvrtv
replic
vero
cell
promis
next
investig
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
whether
propos
drug
therapi
could
inhibit
viru
replic
human
epitheli
pulmonari
cell
line
atv
alon
show
nearli
increas
potenc
inhibit
replic
figur
compar
vero
cell
figur
atvrtv
cq
similarli
potent
inhibit
viru
replic
cell
type
figur
c
atvrtv
atv
cq
ec
valu
inhibit
replic
cell
respect
vitro
result
confirm
ration
would
suscept
atv
includ
cell
deriv
respiratori
tract
recent
report
outbreak
implic
increas
level
lactat
dehydrogenas
ldh
interleukin
associ
mortal
viral
infect
respiratori
tract
often
trigger
migrat
blood
monocyt
orchestr
transit
innat
adapt
immun
respons
reason
atv
atvrtv
test
suboptim
optim
dose
model
util
human
primari
monocyt
atvrtv
cq
similarli
effici
inhibit
viral
replic
human
monocyt
figur
viru
infect
increas
cellular
mortal
prevent
atv
dose
test
atvrtv
figur
control
deterg
treatment
complet
destroy
cell
figur
moreov
observ
infect
trigger
expect
increas
level
cultur
supernat
rang
depend
cell
donor
figur
open
circl
niltreat
cell
virusinduc
enhanc
level
significantli
prevent
treatment
atv
atvrtv
cq
figur
anoth
biomark
uncontrol
proinflammatori
cytokin
respons
upregul
viru
infect
figur
combin
atvrtv
could
significantli
prevent
induct
releas
figur
altogeth
result
confirm
atv
atvrtv
ignor
addit
therapeut
option
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
two
decad
centuri
human
vulner
emerg
viral
diseas
notabl
emerg
infecti
diseas
highlight
undeni
fact
exist
countermeasur
ineffici
prevent
viru
spill
diseas
outbreak
preclin
data
suscept
emerg
viru
clinic
approv
drug
allow
rapid
mobil
resourc
toward
clinic
trial
approach
prove
feasibl
combat
zika
yellow
fever
chikungunya
outbreak
experienc
brazil
past
year
group
demonstr
sofosbuvir
blockbust
drug
hepat
c
could
repres
compassion
countermeasur
diseas
current
rate
dissemin
becom
one
rapidli
evolv
pandem
known
modern
time
number
case
death
doubl
everi
week
peak
pandem
yet
arriv
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
document
bioavail
reach
respiratori
tract
lead
propos
use
pulmonari
fibrosi
throughout
cours
studi
lpvrtvtreat
patient
continu
shed
magnitud
durat
control
group
limit
enthusiasm
part
medic
scientif
commun
therapeut
option
context
atv
andor
atvrtv
ignor
treatment
novel
respiratori
diseas
inde
result
demonstr
potenc
atv
atvrtv
potenc
cell
like
consist
bioavail
lung
experiment
model
highli
pathogen
respiratori
virus
influenza
viru
associ
cytokin
storm
describ
uncontrol
proinflammatori
cytokin
respons
cytokin
storm
also
seem
highli
relev
pathogen
human
cov
contemporari
investig
strongli
suggest
involv
cytokin
storm
diseas
sever
mortal
associ
enhanc
level
consist
cell
death
measur
ldh
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
releas
show
atv
atvrtv
decreas
releas
human
primari
monocyt
moreov
also
includ
analysi
anoth
hallmark
inflamm
respiratori
viru
infect
result
revel
cellular
mortal
cytokin
stormassoci
mediat
reduc
treatment
repurpos
antiretrovir
drug
use
studi
among
promis
drug
cq
lpv
display
higher
toxic
profil
atv
moreov
atv
atvrtv
vitro
antivir
potenc
compar
cq
remdesivir
superior
lpvrtv
summari
studi
highlight
new
option
among
clinic
approv
drug
consid
ongo
clinic
trial
effect
treatment
antivir
atv
atvrtv
cq
receiv
donat
instituto
de
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
african
green
monkey
kidney
vero
subtyp
human
lung
epitheli
cell
cell
cultur
high
glucos
dmem
fetal
bovin
serum
fb
hyclon
logan
utah
uml
penicillin
gml
streptomycin
penstrep
thermofish
humidifi
atmospher
co
human
primari
monocyt
obtain
h
plastic
adher
viru
titer
determin
tissu
cultur
infecti
dose
tcid
ml
viru
stock
kept
ultralow
freezer
viru
strain
sequenc
confirm
viru
ident
complet
genom
publicli
deposit
http
nextstrainorgncov
gisaid
epi
isl
monolay
vero
cell
x
cellwel
plate
infect
logbas
dilut
supernat
contain
cell
wash
fresh
medium
ad
fb
day
post
infect
cytopath
effect
score
least
replic
per
dilut
independ
reader
reader
blind
respect
sourc
supernat
reed
muench
score
method
employ
determin
tcid
ml
total
rna
cultur
extract
use
qiaamp
viral
rna
accord
manufactur
instruct
quantit
rtpcr
perform
use
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
level
ldh
quantifi
monocyt
supernat
infect
uninfect
cell
elisa
requir
supernat
expos
captur
antibodi
plate
incub
period
room
temperatur
rt
detect
antibodi
ad
plate
incub
anoth
rt
streptavidinhrp
substrat
ad
incub
minut
optic
densiti
determin
use
micropl
reader
set
nm
extracellular
lactat
dehydrogenas
ldh
quantifi
use
dole
kit
accord
manufactur
instruct
supernat
centrifug
rpm
minut
remov
cellular
debri
total
supernat
place
plate
incub
ferric
alum
ldh
substrat
minut
nicotinamid
adenin
dinucleotid
nad
oxid
form
ad
follow
addit
stabil
solut
min
incub
plate
measur
spectrophotomet
nm
dock
ligand
perform
box
edg
mass
center
match
complex
peptid
scan
produc
conform
ligand
best
score
use
molecular
dynam
simul
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sinc
tertiari
structur
mpro
homodim
focus
molecular
dynam
one
chain
henceforward
chain
molecular
dynam
calcul
perform
use
namd
forc
field
ph
ie
deproton
glu
asp
proton
arg
ly
neutral
proton
atom
allatom
forc
field
abl
fold
properli
mani
solubl
protein
solubl
protein
center
cubic
box
water
molecul
box
extend
nm
outsid
protein
four
later
side
appropri
number
na
clion
ad
ensur
system
neutral
electrostat
interact
calcul
use
particl
mesh
ewald
method
cutoff
nm
cutoff
nm
use
van
der
waal
interact
nonbond
pair
list
updat
everi
fs
follow
analysi
base
md
simul
ns
k
protein
extract
contain
mpro
activ
obtain
vero
cell
monolay
cm
flask
infect
moi
co
day
infect
supernat
harvest
monolay
wash
time
steril
cold
pb
ph
next
cell
suspend
ml
lysi
buffer
mm
trishcl
ph
mm
nacl
glycerol
triton
kept
solubl
protein
fraction
isol
supernat
centrifug
x
g
min
store
use
protein
concentr
sampl
determin
use
bca
protein
assay
kit
proteinas
assay
electrophoresi
sdspage
copolymer
gelatin
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
assay
perform
blind
one
profession
codifi
read
anoth
profession
experi
carri
least
three
independ
time
includ
minimum
two
technic
replic
assay
doserespons
curv
use
calcul
ec
cc
valu
gener
variabl
slope
plot
prism
graphpad
softwar
equat
fit
best
curv
gener
base
r
valu
student
ttest
use
access
statist
signific
p
valu
statist
analys
specif
softwar
program
use
bioinformat
analysi
describ
experiment
legend
figur
figur
activ
site
mpro
absenc
presenc
inhibitor
repres
structur
mpro
color
code
show
electrostat
potenti
residu
activ
site
neg
blue
posit
red
charg
panel
caviti
ligand
interact
design
absenc
inhibitor
panel
b
placement
lpv
cyan
dock
region
activ
site
panel
c
placement
atv
orang
dock
region
activ
site
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
